The Editas Medicine Mission

Our mission is to translate the power and potential of genome editing into a broad class of gene editing medicines that transform lives of people living with serious diseases.

What We’re Working On

We’re using CRISPR, a powerful genome editing technology to develop new gene edited medicines. We are researching and developing both in vivo gene editing medicines, which edit genes inside the body, and ex vivo gene editing cell medicines, where editing occurs in cells outside the body and those edited cells are transferred into patients.

Gene editing has the potential to change outcomes within a broad range of diseases. Right now, we’re concentrating our efforts on hemoglobinopathies and in vivo editing, including hematopoietic stem cells and other tissue types.

Blood diseases

Sickle cell disease (SCD), Beta thalassemia

Oncology

Advancing cellular therapy assets through partnerships, including continued development of alpha-beta T-cells medicines with Bristol-Myers-Squibb and gamma-delta T-cell medicines with Immatics N.V.

In Vivo Gene Edited Medicines